CLOs on the Move

PanTheryx

www.pantheryx.com

 
PanTheryx, Inc., a U.S. medical nutrition company based in Boulder, Colorado, is dedicated to improving global health and quality of life through innovative science.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.pantheryx.com
  • 5480 Valmont Road Suite 325
    Boulder, CO USA 80301
  • Phone: 303.951.6883

Executives

Name Title Contact Details

Similar Companies

Pfeiffer Pharmaceuticals

Pfeiffer Pharmaceuticals is a Atlanta, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Paratek Pharmaceuticals

Positive outcomes. Positive patient stories. These are our priorities at Paratek Pharmaceuticals. As a commercial-stage biopharmaceutical company, we develop transformative solutions for patients with infectious diseases and other difficult to treat conditions, and we believe that we have the right people, the right knowledge and the right drug to make a difference in patients` lives. Our Mission To create positive stories for patients, physicians and caregivers based on trust and integrity. To accomplish this, our employees work hard to turn everyday decisions into everyday triumphs that advance our technology and strengthen Paratek. Our Vision To be a leading independent biopharmaceutical company providing novel life-saving products for life-threatening diseases or other public health threats.

AstraZeneca

AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England.

Radionetics

Radionetics Oncology is a pharmaceutical company focused on the discovery and development of novel radiotherapeutics for the treatment of a wide range of oncology indications. The company`s platform technology uses nonpeptide, small molecule targeting to deliver therapeutic radioisotopes to a broad range of cancers by binding selectively to peptide receptors that are selectively expressed on these tumors. This nonpeptide technology addresses many of the significant challenges currently facing peptide and protein targeted radiotherapeutics, particularly in the realm of optimizing drug-like characteristics and manufacturing. The company is rapidly advancing a pipeline of drug candidates to treat a broad range of cancers and is conducting additional drug discovery efforts to identify drug candidates for additional receptor targets in collaboration with Crinetics Pharmaceuticals.